tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Buy Rating for Jiangsu Hengrui Pharmaceuticals Driven by Strategic Out-Licensing and Promising HRS-1893 Data
PremiumRatingsPositive Buy Rating for Jiangsu Hengrui Pharmaceuticals Driven by Strategic Out-Licensing and Promising HRS-1893 Data
2M ago
Jiangsu Hengrui Pharmaceuticals Licenses Innovative Drug to Braveheart Bio
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Licenses Innovative Drug to Braveheart Bio
2M ago
Jiangsu Hengrui’s Innovative Drug Receives Conditional Approval
Premium
Company Announcements
Jiangsu Hengrui’s Innovative Drug Receives Conditional Approval
2M ago
Jiangsu Hengrui Pharmaceuticals Approves 2025 Employee Stock Ownership Scheme
PremiumCompany AnnouncementsJiangsu Hengrui Pharmaceuticals Approves 2025 Employee Stock Ownership Scheme
3M ago
Jiangsu Hengrui Pharmaceuticals Announces Upcoming Board Meeting for Interim Results
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Announces Upcoming Board Meeting for Interim Results
3M ago
Jiangsu Hengrui Pharmaceuticals Partners with GSK for Global Licensing Agreement
Premium
Company Announcements
Jiangsu Hengrui Pharmaceuticals Partners with GSK for Global Licensing Agreement
3M ago
Jiangsu Hengrui Gains Approval for Innovative Cancer Drug
PremiumCompany AnnouncementsJiangsu Hengrui Gains Approval for Innovative Cancer Drug
5M ago
Jiangsu Hengrui’s Innovative Antiemetic Drug Gains Approval
Premium
Company Announcements
Jiangsu Hengrui’s Innovative Antiemetic Drug Gains Approval
5M ago
Jiangsu Hengrui’s Innovative Lung Cancer Drug Gains Conditional Approval in China
Premium
Company Announcements
Jiangsu Hengrui’s Innovative Lung Cancer Drug Gains Conditional Approval in China
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100